| The effect of PAI‐1 4G/5G polymorphism and clinical factors on coronary artery occlusion in myocardial infarction TK Parpugga, V Tatarunas, V Skipskis, N Kupstyte, ... Disease markers 2015 (1), 260101, 2015 | 49 | 2015 |
| The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy V Tatarunas, L Jankauskiene, N Kupstyte, V Skipskis, O Gustiene, ... Blood Coagulation & Fibrinolysis 25 (4), 369-374, 2014 | 38 | 2014 |
| Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals E Danese, S Raimondi, M Montagnana, A Tagetti, T Langaee, P Borgiani, ... Clinical Pharmacology & Therapeutics 105 (6), 1477-1491, 2019 | 37 | 2019 |
| The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery V Tatarunas, V Lesauskaite, A Veikutiene, P Grybauskas, P Jakuska, ... Journal of thrombosis and thrombolysis 37, 177-185, 2014 | 37 | 2014 |
| The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement V Tatarūnas, V Lesauskaitė, A Veikutienė, P Jakuška, R Benetis Medicina 47 (1), 4, 2011 | 35 | 2011 |
| Matrix metalloproteinase-3 gene polymorphism and dilatative pathology of ascending thoracic aorta V Lesauskaitė, G Šinkūnaitė, R Benetis, V Grabauskas, J Vaškelytė, ... Medicina 44 (5), 386, 2008 | 31 | 2008 |
| Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis N Kupstyte, R Zaliunas, V Tatarunas, V Skipskis, ... Pharmacogenomics 16 (3), 181-189, 2015 | 28 | 2015 |
| The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy V Tatarunas, N Kupstyte, R Zaliunas, A Giedraitiene, V Lesauskaite Pharmacogenomics 18 (10), 969-979, 2017 | 27 | 2017 |
| Current antimicrobial susceptibility testing for beta-lactamase-producing Enterobacteriaceae in clinical settings L Pereckaite, V Tatarunas, A Giedraitiene Journal of microbiological methods 152, 154-164, 2018 | 26 | 2018 |
| Retinal and choroidal thinning—a predictor of coronary artery occlusion? I Matulevičiūtė, A Sidaraitė, V Tatarūnas, A Veikutienė, O Dobilienė, ... Diagnostics 12 (8), 2016, 2022 | 16 | 2022 |
| CTX-M-producing Escherichia coli strains: resistance to temocillin, fosfomycin, nitrofurantoin and biofilm formation A Giedraitiene, L Pereckaite, E Bredelyte-Gruodiene, M Virgailis, ... Future Microbiology 17 (10), 789-802, 2022 | 16 | 2022 |
| The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy V Tatarunas, N Kupstyte-Kristapone, R Norvilaite, V Tamakauskas, ... Pharmacogenomics 20 (7), 483-492, 2019 | 14 | 2019 |
| New potential modulators of CYP4F2 enzyme activity in angina pectoris: Hsa-miR-24-3p and hsa-miR-34a-5p D Gecys, V Tatarunas, A Veikutiene, V Lesauskaite Biomarkers 25 (1), 40-47, 2020 | 12 | 2020 |
| Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome V Tatarunas, N Kupstyte-Kristapone, V Zvikas, V Jakstas, R Zaliunas, ... Scientific reports 10 (1), 3175, 2020 | 10 | 2020 |
| Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration R Liutkeviciene, A Vilkeviciute, A Slavinskaite, A Petrauskaite, ... Gene 676, 139-145, 2018 | 10 | 2018 |
| The combined effects of clinical factors and CYP2C9 and VKORC1 gene polymorphisms on initiating warfarin treatment in patients after cardiac valve surgery. V Tatarūnas, V Lesauskaite, A Veikutiene, P Grybauskas, P Jakuska, ... The Journal of heart valve disease 21 (5), 628-635, 2012 | 9 | 2012 |
| SARS-CoV-2 infection, sex-related differences, and a possible personalized treatment approach with valproic acid: a review D Stakišaitis, L Kapočius, A Valančiūtė, I Balnytė, T Tamošuitis, ... Biomedicines 10 (5), 962, 2022 | 8 | 2022 |
| The impact of CYP2C19* 2, CYP4F2* 3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated … V Tatarunas, N Kupstyte, A Giedraitiene, V Skipskis, V Jakstas, V Zvikas, ... Blood Coagulation & Fibrinolysis 28 (8), 658-664, 2017 | 8 | 2017 |
| Assessment of absorption of glycated nail proteins in patients with diabetes mellitus and diabetic retinopathy I Jurgeleviciene, D Stanislovaitiene, V Tatarunas, M Jurgelevicius, ... Medicina 56 (12), 658, 2020 | 7 | 2020 |
| The impact of trimethylamine N-Oxide and coronary microcirculatory dysfunction on outcomes following ST-elevation myocardial infarction A Aldujeli, R Patel, I Grabauskyte, A Hamadeh, A Lieponyte, V Tatarunas, ... Journal of Cardiovascular Development and Disease 10 (5), 197, 2023 | 6 | 2023 |
